These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 27702836

  • 1. The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis.
    Cong L, Wang S, Gao T, Hu L.
    Jpn J Clin Oncol; 2016 Dec; 46(12):1118-1126. PubMed ID: 27702836
    [Abstract] [Full Text] [Related]

  • 2. FDG PET using SUVmax for preoperative T-staging of esophageal squamous cell carcinoma with and without neoadjuvant chemoradiotherapy.
    Huang YC, Lu HI, Huang SC, Hsu CC, Chiu NT, Wang YM, Chiu YC, Li SH.
    BMC Med Imaging; 2017 Jan 05; 17(1):1. PubMed ID: 28056868
    [Abstract] [Full Text] [Related]

  • 3. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW, van Lanschot JJ.
    Ann Surg; 2011 Jan 05; 253(1):56-63. PubMed ID: 21233607
    [Abstract] [Full Text] [Related]

  • 4. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
    Sakai M, Sohda M, Miyazaki T, Honjo H, Hara K, Ozawa D, Suzuki S, Tanaka N, Yokobori T, Kuwano H.
    Hepatogastroenterology; 2015 Jun 05; 62(140):898-901. PubMed ID: 26902024
    [Abstract] [Full Text] [Related]

  • 5. Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma.
    Hamai Y, Hihara J, Emi M, Furukawa T, Yamakita I, Kurokawa T, Okada M.
    Ann Thorac Surg; 2016 Oct 05; 102(4):1132-9. PubMed ID: 27319990
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Can ¹⁸F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis.
    Chen YM, Pan XF, Tong LJ, Shi YP, Chen T.
    Nucl Med Commun; 2011 Nov 05; 32(11):1005-10. PubMed ID: 21886014
    [Abstract] [Full Text] [Related]

  • 8. Prognostic and predictive values of interim 18F-FDG PET during neoadjuvant chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis.
    Han S, Kim YI, Woo S, Kim TH, Ryu JS.
    Ann Nucl Med; 2021 Apr 05; 35(4):447-457. PubMed ID: 33471289
    [Abstract] [Full Text] [Related]

  • 9. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
    Yap WK, Chang YC, Tseng CK, Hsieh CH, Chao YK, Su PJ, Hou MM, Yang CK, Pai PC, Lin CR, Hsieh CE, Wu YY, Hung TM.
    Dis Esophagus; 2017 Aug 01; 30(8):1-10. PubMed ID: 28575243
    [Abstract] [Full Text] [Related]

  • 10. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M, Alnaji RM, Jabi F, Platz TA, Attwood K, Nava H, Ben-David K, Mattson D, Salerno K, Malhotra U, Kanehira K, Gannon J, Hochwald SN.
    JAMA Surg; 2015 Jun 01; 150(6):555-62. PubMed ID: 25902198
    [Abstract] [Full Text] [Related]

  • 11. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C.
    Ann Surg; 2013 Jul 01; 258(1):66-76. PubMed ID: 23470576
    [Abstract] [Full Text] [Related]

  • 12. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
    Stiekema J, Vermeulen D, Vegt E, Voncken FE, Aleman BM, Sanders J, Boot H, van Sandick JW.
    Clin Nucl Med; 2014 Oct 01; 39(10):862-7. PubMed ID: 25140549
    [Abstract] [Full Text] [Related]

  • 13. Role of 18F-FDG-PET/CT in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
    Sasaki K, Uchikado Y, Okumura H, Omoto I, Kita Y, Arigami T, Uenosono Y, Owaki T, Maemura K, Natsugoe S.
    Anticancer Res; 2017 Feb 01; 37(2):859-864. PubMed ID: 28179343
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of quantitative parameters for esophageal squamous cell carcinoma determined by preoperative FDG-PET after trimodal therapy.
    Hamai Y, Emi M, Ibuki Y, Murakami Y, Nishibuchi I, Nagata Y, Kurokawa T, Yoshikawa T, Hirohata R, Ohsawa M, Kitasaki N, Okada M.
    Surgery; 2022 Aug 01; 172(2):584-592. PubMed ID: 35523595
    [Abstract] [Full Text] [Related]

  • 15. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography.
    Brücher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, Werner M, Zimmerman F, Siewert JR, Schwaiger M.
    Ann Surg; 2001 Mar 01; 233(3):300-9. PubMed ID: 11224616
    [Abstract] [Full Text] [Related]

  • 16. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis.
    Kroese TE, Goense L, van Hillegersberg R, de Keizer B, Mook S, Ruurda JP, van Rossum PSN.
    Dis Esophagus; 2018 Dec 01; 31(12):. PubMed ID: 29917073
    [Abstract] [Full Text] [Related]

  • 17. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review.
    Kwee RM.
    Radiology; 2010 Mar 01; 254(3):707-17. PubMed ID: 20177086
    [Abstract] [Full Text] [Related]

  • 18. Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-analysis.
    Eyck BM, Onstenk BD, Noordman BJ, Nieboer D, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB.
    Ann Surg; 2020 Feb 01; 271(2):245-256. PubMed ID: 31188203
    [Abstract] [Full Text] [Related]

  • 19. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M, Neoral C, Vrba R, Vomackova K, Cincibuch J, Formanek R, Koranda P, Zapletalova J.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun 01; 156(2):171-9. PubMed ID: 22660205
    [Abstract] [Full Text] [Related]

  • 20. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
    Higuchi I, Yasuda T, Yano M, Doki Y, Miyata H, Tatsumi M, Fukunaga H, Takiguchi S, Fujiwara Y, Hatazawa J, Monden M.
    J Thorac Cardiovasc Surg; 2008 Jul 01; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.